Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

New treatment for recurring malaria approved
P.vivax malaria is found mainly in the US, Latin America and some parts of Africa.
Single-dose Krintafel to prevent relapse of P. vivax malaria

A new vaccine for the treatment of recurring malaria has been approved by the United States Food and Drug Administration.

A press release issued by GlaxoSmithKline (GSK) and Medicines for Malaria Venture (MMV) said that single-dose Krintafel (tafenoquine) will be the first to prevent against a relapse of P. vivax malaria.  

“Today’s approval of Krintafel, the first new treatment for Plasmodium vivax malaria in over 60 years, is a significant milestone for people living with this type of relapsing malaria,” explained Dr Hal Barron, GSK chief scientific officer and president of research and development.

“Together with our partner, Medicines for Malaria Venture, we believe Krintafel will be an important medicine for patients with malaria and contribute to the ongoing effort to eradicate this disease.”

MMV chief executive officer Dr David Reddy hailed the US FDA’s approval of Krintafel as a ‘major milestone’ and a ‘significant contribution’ towards the global eradication of malaria.

“The world has waited decades for a new medicine to counter P. vivax malaria relapse,” he said. “Today, we can say the wait is over. Moreover, as the first ever single-dose for this indication, Krintafel will help improve patient compliance.

“We are proud to have worked side-by-side with GSK for more than a decade to reach this point. Our focus is now on working to ensure the medicine reaches the vulnerable patients that need it most.”

The most frequent and widely distributed causes of recurring malaria, p.vivax is one of the six species of parasite that commonly infects humans. Found mainly in the US, Latin America and some parts of Africa, it can lay dormant in the liver for several months or years after the infecting bite. 

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
RCVS Regional Question Time heads to Edinburgh

The RCVS is to bring its Regional Question Time (RQT) to Edinburgh for 2026.

The event will take place at Novotel Edinburgh Park in Edinburgh on Wednesday, 20 May 2026.

It will begin with supper and drinks at 6.30pm, with an evening programme from 7.30pm. This will start with an update on RCVS' activities, followed by questions and answers with representatives.

RCVS is encouraging an 'open dialogue', in which queries can be raised in a friendly, informal environment.

While discussions are expected to be audience-led, the RQT is expected address major issues including the VSA, the CMA's remedy package and the VN Vision project.

Tim Parkin, RCVS president, said: "It's an important time for the professions, and I'm looking forward to meeting colleagues in Scotland as we navigate this period of change together so we can come out stronger."

Tickets can be booked here.